Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents: 2022-2024

Historic Cash & Equivalents for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Dec 2024 value amounting to $383.2 million.

  • Centessa Pharmaceuticals' Cash & Equivalents fell 87.14% to $50.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.8 million, marking a year-over-year decrease of 87.14%. This contributed to the annual value of $383.2 million for FY2024, which is 199.32% up from last year.
  • As of FY2024, Centessa Pharmaceuticals' Cash & Equivalents stood at $383.2 million, which was up 199.32% from $128.0 million recorded in FY2023.
  • Centessa Pharmaceuticals' Cash & Equivalents' 5-year high stood at $393.6 million during FY2022, with a 5-year trough of $128.0 million in FY2023.
  • In the last 3 years, Centessa Pharmaceuticals' Cash & Equivalents had a median value of $383.2 million in 2024 and averaged $301.6 million.
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Cash & Equivalents slumped by 67.48% in 2023, and later soared by 199.32% in 2024.
  • Centessa Pharmaceuticals' Cash & Equivalents (Yearly) stood at $393.6 million in 2022, then slumped by 67.48% to $128.0 million in 2023, then spiked by 199.32% to $383.2 million in 2024.